CEO of RNL Bio unveils tender offer

Published: 2013-05-02 06:56:00

Updated: 2013-05-02 06:56:00

RNL Bio president Ra Jung-chan said last Friday that he will acquire a 50 percent stake of existing shareholders through tender offer. The tender offer is a public, open offer or invitation by a prospective acquirer to all stockholders of a publicly traded corporation to tender their stock for sa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK